Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Dihexa | DSIP (Delta Sleep-Inducing Peptide) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 10-20 mg daily via oral or sublingual administration. | Research indicates 100-300 mcg administered before bedtime via subcutaneous injection or intranasal. |
| Timing | Morning dosing preferred. Can be taken with or without food (orally active). | 30-60 minutes before desired sleep onset. Evening only. |
| Cycle Duration | 2-4 week cycles with equal rest periods. Long-term safety data is extremely limited. | 2-4 week cycles with equal rest periods to prevent tolerance. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is an orally active, blood-brain barrier-permeable oligopeptide derived from angiotensin IV. It binds hepatocyte growth factor (HGF) with high affinity, inhibiting HGF dimerization and synergistically promoting c-Met receptor phosphorylation and signaling. Activation of HGF/c-Met drives procognitive effects through increased dendritic arborization, spinogenesis, and synaptogenesis via the PI3K/AKT signaling pathway. Research indicates it is approximately 10 million times more potent than BDNF for new synapse formation.
Research indicates 10-20 mg daily via oral or sublingual administration.
Morning dosing preferred. Can be taken with or without food (orally active).
2-4 week cycles with equal rest periods. Long-term safety data is extremely limited.
DSIP is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from rabbit brain hypothalamus in 1977. It modulates GABAergic neurotransmission by potentiating GABA-activated currents in hippocampal and cerebellar neurons while blocking NMDA-activated potentiation in cortical neurons. It also interacts with opioid-associated receptors, modulates serotonin and dopamine systems (increasing serotonin levels), and promotes delta wave (slow-wave) sleep through mechanisms that remain incompletely characterized.
Research indicates 100-300 mcg administered before bedtime via subcutaneous injection or intranasal.
30-60 minutes before desired sleep onset. Evening only.
2-4 week cycles with equal rest periods to prevent tolerance.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →